GelStat Corporation reported consolidated earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported consolidated revenue of $542,477, up 8,800% from $6,157 for the third quarter ended September 30, 2013. Net loss was $457,935 compared to a loss of $28,115 for the third quarter ended September 30, 2013. Net losses for the period ended September 30, 2014 included over $400,000 in non-cash charges.

The company increased revenue forecast to over $750,000 for the fourth quarter ending December 31, 2014. The increased revenue expectations are driven by continued strength in operations from recently acquired wholly owned subsidiary Mastix Medica and increasing sales of proprietary healthcare products.